Stapokibart

BIOLOGICAL5 trials

Sponsors

Keymed Biosciences Co.Ltd, Beijing Tongren Hospital, First Affiliated Hospital of Chongqing Medical University, Chengdu Kangnuoxing Biopharma,Inc.

Conditions

Biological TherapyBiomarkersCRSWNPChronic Rhinosinusitis with Nasal Polyps (CRSwNP)Primary Cutaneous AmyloidosisPrurigo NodularisSAR

Phase 3

Study on the Treatment of Prurigo Nodularis With Stapokibart Injection

Active, not recruitingNCT06424470

Keymed Biosciences Co.LtdPrurigo Nodularis

Start: 2024-06-25End: 2026-07-30Updated: 2025-05-22

Phase 4

A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps

Not yet recruitingNCT06801353

Beijing Tongren HospitalBiological Therapy, Biomarkers, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Start: 2025-02-01End: 2026-07-01Target: 90Updated: 2025-02-06

Unknown Phase

Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis

Not yet recruitingNCT07143864

First Affiliated Hospital of Chongqing Medical UniversityPrimary Cutaneous Amyloidosis

Start: 2025-09-15End: 2026-12-31Target: 40Updated: 2025-08-27

A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)

Not yet recruitingNCT07459556

Chengdu Kangnuoxing Biopharma,Inc.SAR

Start: 2026-03-01End: 2028-02-01Target: 400Updated: 2026-03-09

A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) .

Not yet recruitingNCT07483268

Chengdu Kangnuoxing Biopharma,Inc.CRSWNP

Start: 2026-06-01End: 2028-02-01Target: 600Updated: 2026-03-19